- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | NewcelX Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| NEWCELX Aktie jetzt für 0€ handeln | |||||
| 13.07. | Laidlaw initiates NewcelX stock with buy rating on diabetes therapy | 1 | Investing.com | ||
| 08.07. | NewcelX beruft Diabetes-Forscher Ricordi in den wissenschaftlichen Beirat | 1 | Investing.com Deutsch | ||
| 08.07. | NewcelX appoints diabetes researcher Ricordi to advisory board | 1 | Investing.com | ||
| 08.07. | NewcelX Ltd.: NewcelX Appoints World-Renowned Diabetes Cure-Focused Pioneer, Dr. Camillo Ricordi, to Scientific Advisory Board | 2 | GlobeNewswire (USA) | ||
| 08.07. | NewcelX Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 01.07. | NewcelX Ltd.: NewcelX Announces Successful FDA Pre-IND Meeting with Clear Path Forward for NCEL-101 Toward Starting Clinical Trials for Type 1 Diabetes | 301 | GlobeNewswire (Europe) | ZURICH, July 01, 2026 (GLOBE NEWSWIRE) -- NewcelX Ltd. ("NewcelX"; Nasdaq: NCEL), a clinical-stage regenerative medicine company developing stem-cell-derived therapies, announced the successful completion... ► Artikel lesen | |
| 30.06. | NewcelX Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 15.06. | NewcelX Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 05.06. | NewcelX Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 27.05. | NewcelX Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 27.05. | NewCelX Ltd. Submits Pre-IND Package to the FDA for NCEL-101 for the Treatment of Type 1 Diabetes | 601 | GlobeNewswire (Europe) | Pre-IND meeting has been scheduled with FDA to advance type 1 diabetes treatment to First-In-Human clinical trial ZURICH, Switzerland, May 27, 2026 (GLOBE NEWSWIRE) -- NewcelX Ltd. ("NewcelX"; Nasdaq:... ► Artikel lesen | |
| 27.05. | EXCLUSIVE: NewcelX Advances Diabetes Therapy Toward Human Trials With FDA Pre-IND Submission | 2 | Benzinga.com | ||
| 06.05. | NewcelX akquiriert bis zu 3,4 Millionen Dollar | 1 | punkt4.info | ||
| 01.05. | NLS Pharmaceutics GAAP EPS of -$2.16 | 1 | Seeking Alpha | ||
| 30.04. | NewcelX Ltd.: NewcelX Reports Financial Results for 2025 and Provides Shareholders with Update on Accelerated Development of Type 1 Diabetes Treatment in Collaboration with Eledon Pharmaceuticals in 2026 | 495 | GlobeNewswire (Europe) | NewcelX and Eledon Pharmaceuticals are collaborating to advance one of the few scalable approaches to a potential functional cure in Type 1 Diabetes, NCEL-101, as the flagship program and key long-term... ► Artikel lesen | |
| 30.04. | EXCLUSIVE: NewcelX Eyes Accelerated 2026 Execution For Diabetes Drug | 3 | Benzinga.com | ||
| 30.04. | NewcelX Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 20.04. | NewcelX informiert über Fortschritte bei Diabetes-Therapie-Kooperation | 2 | Investing.com Deutsch | ||
| 20.04. | NewcelX updates presentation on diabetes therapy collaboration | 3 | Investing.com |
1 2 3 Weiter >>
47 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NOVAVAX | 7,060 | +2,17 % | Novavax (NVAX) Registers a Bigger Fall Than the Market: Important Facts to Note | ||
| PALATIN TECHNOLOGIES | 8,710 | +1,28 % | Palatin Technologies, Inc.: Palatin to Begin Trading on Nasdaq Stock Exchange | PRINCETON, N.J., May 18, 2026 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company focused on the discovery and development... ► Artikel lesen | |
| OCUGEN | 1,136 | -3,73 % | Ocugen, Inc. Announces Binding Term Sheet with Roots Pharmaceutical to License OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa | Cumulative sales milestones up to $255 million and modest upfront/near-term development milestonesRoyalties equaling 22% of net salesOcugen to manufacture and supply OCU400 MALVERN, Pa., July 13,... ► Artikel lesen | |
| NUREXONE BIOLOGIC | 0,327 | +5,14 % | NurExone öffnet mit Exo-Top die Tür zum mexikanischen Exosomenmarkt | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,242 | +4,55 % | PacBio to Report Second Quarter 2026 Financial Results on August 5, 2026 | ||
| REDHILL BIOPHARMA | 0,720 | +2,86 % | RedHill Biopharma Ltd.: RedHill's Opaganib Receives FDA Rare Pediatric Disease Designation for Neuroblastoma in Addition to Current Orphan Drug Designation | The U.S. Food and Drug Administration (FDA) has granted rare pediatric disease designation to opaganib1 for the treatment of neuroblastoma, a type of cancer most... ► Artikel lesen | |
| ONCO-INNOVATIONS | 0,411 | +2,88 % | Onco-Innovations Ltd: Onco-Innovations begins studies to develop ONC010 | ||
| NOVOCURE | 13,960 | -0,11 % | Novocure to Report Second Quarter 2026 Financial Results | Novocure (NASDAQ: NVCR) will report financial results for the second quarter 2026 on July 23, 2026, before the U.S. financial markets open.
Novocure management will host a conference call and webcast... ► Artikel lesen | |
| REVOLUTION MEDICINES | 160,95 | +1,83 % | Revolution Medicines: Nach Bauchspeicheldrüsenkrebs-Durchbruch - geht jetzt alles ganz schnell? | Eine Revolution im wahrsten Sinne des Unternehmensnamens: Die Biotech-Gesellschaft Revolution Medicines kann einen Paradigmenwechsel zur Behandlung von Bauchspeicheldrüsenkrebs einleiten. Die Datenlage... ► Artikel lesen | |
| OCULAR THERAPEUTIX | 7,850 | +2,61 % | Citizens reiterates Ocular Therapeutix stock rating on Dextenza sales | ||
| ROCKET PHARMACEUTICALS | 2,930 | -2,33 % | ROCKET PHARMACEUTICALS, INC. - S-8, Securities to be offered to employees in employee benefit plans | ||
| PALISADE BIO | 1,915 | +0,26 % | Palisade Bio, Inc.: Palisade Bio Receives FDA Clearance of IND for PALI-2108 and Plans to Initiate Global Phase 2 ASCENTRA-UC Study in Ulcerative Colitis | ASCENTRA-UC expected to enroll up to 204 patients with moderately to severely active ulcerative colitis across North America and Europe First patient enrollment anticipated in the second half of 2026... ► Artikel lesen | |
| ONCOLYTICS BIOTECH | 0,860 | +1,13 % | FDA grants fast track status to Oncolytics' anal cancer therapy | ||
| OUTLOOK THERAPEUTICS | 1,252 | +3,90 % | Outlook Therapeutics, Inc. - 8-K, Current Report | ||
| REGENXBIO | 9,088 | +0,58 % | Clinical Trial Results Show Extended Benefits for REGENXBIO Retinal Treatments |
NEWCELX LTD gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von -0,160 (-4,03 %) liegt der Kurs bei 3,810 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NEWCELX LTD finden Sie auf Wallstreet Online.